We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Brings Its Latest Innovations in Laboratory Diagnostics to MEDLAB Middle East 2022

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: epoc Blood Analyzer (Photo courtesy of Siemens Healthineers)
Image: epoc Blood Analyzer (Photo courtesy of Siemens Healthineers)

Siemens Healthineers (Erlangen, Germany) presented its latest innovations in laboratory diagnostics, including automation solutions for labs of all sizes, virtually as well as live, at the 2022 edition of MEDLAB Middle East.

Siemens demonstrated its Atellica hematology portfolio that pairs automation, intelligence, and extended parameters to streamline operations and support accurate clinical decision-making. The company displayed its two new flagship hematology analyzers - Atellica HEMA 570 and 580 - that are designed to deliver reliable performance targeted for high volume routine workloads. Also on display was the Atellica Solution comprising flexible, scalable, automation-ready immunoassay and chemistry analyzers with integrated automation. Atellica Integrated Automation (AIA) on the Atellica Solution consolidates revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint.

In addition, Siemens highlighted its Sysmex CN-3000 and CN-6000 fully automated, mid- and high-volume coagulation analyzers that help meet the small-sized, mid- and high-volume hemostasis testing solutions to tackle big lab challenges. Giants on the inside, combining size, speed, intelligence, and flexibility, the Sysmex CN Systems help transform care delivery through improved workforce productivity.

Siemens demonstrated how Atellica Diagnostics IT provides scalable, easy-to-use solutions to simplify tasks and maximize the effectiveness of the laboratory and its staff. Viewers learnt how Atellica Diagnostics IT can enhance visibility, automate processes, and centralize management across instruments, automation, sites, and networks. Siemens also demonstrated Atellica Inventory Manager, its real-time automated inventory management solution that provides automated, real-time control of reagents and consumables across multiple locations to reduce costs, save time, and improve lab quality. Other lab products highlighted by Siemens at MEDLAB Middle East 2022 included the INNOVANCE VWF Ac assay which sets a new standard in VWF activity determination and its robust menu of inflammatory markers (including a key marker, IL-6) and other lab tests to assess tissue and organ damage that can help clinicians understand the severity of the COVID-19 disease as well as implement timely interventions for patients at risk for cytokine storm.

Related Links:
Siemens Healthineers

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more